slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 5,521-5,550
Pages 296
Rows per page 30
Slide type
5,521-5,550 of 8,880
34
The slide uses a linear process flow to demonstrate the platform's capabilities.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
35
The slide explains the mechanism of incorporating nsAA into mAbs to create ADC precursors.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
36
The slide uses a split-column layout to contrast the platform's technical capability with its practical application.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
37
The slide uses a series of diagrams to illustrate the biological engineering features of the cell line.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
40
Uses a four-column layout to categorize value propositions.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
41
PoS stands for Probability of Success. The slide uses a timeline framework to contrast traditional drug development with Absci's approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
10
The chart compares Cyno Half-Life vs Human Half-Life, showing YTE mAbs outperforming WT mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
11
The slide uses a 'before-after' logic to justify the combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
12
Uses a Venn diagram to show target overlap and a bar chart to show clinical efficacy improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
18
The slide uses a central antibody diagram to annotate specific technical improvements over 1st generation mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
Includes structural biology visualization and dose-response curves for two different adhesion targets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
35
The slide uses two charts: a dose-response curve (left) and a scatter plot (right) to demonstrate competitive advantage.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
36
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
37
The visual uses a mountain-climbing metaphor to represent indication expansion.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
39
The slide uses a biological process diagram to illustrate the mechanism of action for three drug candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
43
The slide uses a Y-shaped antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
44
The slide uses a Venn diagram to illustrate target overlap and a tree diagram to show potential combination therapy paths.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
53
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a pentagon diagram to represent the five pillars of their antibody engineering platform.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
55
The diagram illustrates the mechanism of FcRn-mediated antibody recycling, contrasting physiological affinity with high affinity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
56
Includes two distinct chart types: a scatter plot for half-life correlation and bar charts for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
05
The slide uses a high-contrast blue box to highlight the core product value proposition.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
Highlights the repurposing of the active ingredient in Viagra for a new indication with no current FDA-approved treatments.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
The diagram uses a hub-and-spoke model centered on a human silhouette representing precision medicine.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The diagram uses a complex flow-chart style with a central infinity loop representing the 'learning' aspect of the AI architecture.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
The slide uses a fan-like layout to show the integration of different technological approaches.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit